Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:eli_lilly [2022/01/17 12:27]
liam
+++ pharmaceutical_companies:eli_lilly [2022/05/04 19:48] (current)
liam [COVID-19]
@@ Line 3: / Line 3: @@
 {{ :pharmaceutical_companies:1200px-eli_lilly_and_company.svg.png?150|}}
-Eli Lilly has Emergency Use Authorization from the U.S. [[Food and Drug Administration]] for three experimental [[:COVID-19]] drugs: Bamlanivimab, Etesevimab and Olumiant (in combination with Remdesivir).
+**Eli Lilly & Company** is an American [[pharmaceutical companies|pharmaceutical company]] based in [[:united_states_of_america:Indiana:Indianapolis]], [[:united_states_of_america:Indiana]].
-The company partnered with [[Amgen]] to manufacture their COVID-19 antibody therapy products. Eli Lilly is also part of the [[:COVID-19 Therapeutics Accelerator]] funded by the [[:Bill & Melinda Gates Foundation]], [[:Wellcome Trust]], and [[:Mastercard]] to “accelerate treatments, [[:vaccines]], and diagnostics”.
+===== History =====
+==== Bush Family ====
+Former U.S. President [[:George H.W. Bush]] was a member of the board of directors.((Levine, B. (2004, May). //Eli Lilly, Zyprexa, & the Bush Family.// Z Magazine. https://archive.ph/dIGJx))
+===== Portfolio =====
+Eli Lilly has an exclusive worldwide licensing agreement with [[Centrexion Therapeutics]] for CNTX-0290, a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist. At the time of the deal, it was in clinical trials as a potential non-opioid treatment for chronic pain conditions.((Taylor, M., Hern, K., Normart, J., & Dugan, C. (2019, May 28). //Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics.// Eli Lilly. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-licensing-agreement-non-opioid-pain-asset))
+==== COVID-19 ====
+Eli Lilly has Emergency Use Authorization from the U.S. [[:Food and Drug Administration]] for three experimental [[:COVID-19]] drugs: Bamlanivimab, Etesevimab and Olumiant (in combination with [[covid-19:treatments:drug_therapies:remdesivir]]).((O’Shaughnessy, J. A., PhD. (2021, December 3). //RE: Emergency Use Authorization 094.// Eli Lilly. Retrieved December 6, 2021, from
+http://pi.lilly.com/eua/bam-and-ete-eua-fda-authorization-letter.pdf)) ((Hinton, D. M. (2021, July 28). //Baricitinib EUA FDA Authorization Letter.// Eli Lilly. Retrieved December 6, 2021, from
+http://pi.lilly.com/eua/baricitinib-eua-fda-authorization-letter.pdf))
+Eli Lilly partnered with [[Amgen]] to manufacture their COVID-19 antibody therapy products.((Taylor, M., & Rowland, T. (2020, September 17). //Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies.// Amgen. https://archive.ph/pXXV5)) A similar partnership exists with [[pharmaceutical_companies:AbCellera]], which recently led to the release of a second product called [[pharmaceutical_products:Bebtelovimab]], alleged to work against [[SARS-CoV-2:Omicron]].((Yingling, J. (2022, February 10). //Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments.// AbCellera. https://archive.ph/odx6M))
+Eli Lilly is also part of the [[:COVID-19 Therapeutics Accelerator]] funded by the [[:Bill & Melinda Gates Foundation]], [[:Wellcome Trust]], and [[:Mastercard]] to “accelerate treatments, [[:vaccines]], and diagnostics.”((Staines, R. (2020, March 26). //Pharma giants including Novartis collaborate on COVID-19 therapies.// Pharmaphorum; Pharmaphorum Media Limited. https://archive.ph/8TAzM))